



Ymddiriedolaeth GIG
Prifysgol Felindre
Velindre University
NHS Trust



Pencadlys Ymddiriedolaeth GIG Prifysgol Felindre
Velindre University NHS Trust Headquarters
2 Cwrt Charnwood
Heol Billingsley
Parc Nantgarw
Caerdydd/Cardiff
CF15 7QZ
Ffôn/Phone : (029) 20196161
<https://velindre.nhs.wales>

Date: 21st November 2024
Ref: CORP 2024 - 218

Dear xxxx

Freedom of Information request: Treatment of Urothelial Cancer (CORP 2024 – 218)

Thank you for your request for information which the Trust received on 4th November 2024.

Your Request:

I am currently analysing trends in cancer treatments across the UK. Could you please answer the following questions:

Question One:

How many patients were treated for Urothelial cancer (any stage) in the past 3 months with the following treatments:

- ***Atezolizumab (Tecentriq)***
- ***Avelumab (Bavencio)***
- ***Carboplatin single agent or in any other combination***
- ***Carboplatin with Gemcitabine***
- ***Carboplatin with Paclitaxel***
- ***Cisplatin single agent or in any other combination***
- ***Cisplatin with Gemcitabine***
- ***Cisplatin with Gemcitabine + Nivolumab (Opdivo)***
- ***Enfortumab Vedotin + Pembrolizumab (Padcev + Keytruda)***
- ***Nivolumab (Opdivo)***
- ***Pembrolizumab (Keytruda)***
- ***Other active systemic anti-cancer therapy***
- ***Palliative care only***

Question Two:


Does your trust participate in any ongoing clinical trials for the treatment of urothelial cancer? If so, can you please provide the name of each trial along with the number of patients taking part?

Please find the Trust's response below:

Question One:

How many patients were treated for Urothelial cancer (any stage) in the past 3 months with the following treatments:

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg. Velindre University NHS Trust is happy to receive communication in Welsh or English.




- **Atezolizumab (Tecentriq)**
- **Avelumab (Bavencio)**
- **Carboplatin single agent or in any other combination**
- **Carboplatin with Gemcitabine**
- **Carboplatin with Paclitaxel**
- **Cisplatin single agent or in any other combination**
- **Cisplatin with Gemcitabine**
- **Cisplatin with Gemcitabine + Nivolumab (Opdivo)**
- **Enfortumab Vedotin + Pembrolizumab (Padcev + Keytruda)**
- **Nivolumab (Opdivo)**
- **Pembrolizumab (Keytruda)**
- **Other active systemic anti-cancer therapy**
- **Palliative care only**

Diagnosis	Regimen	Patients
Adjuvant Urothelial Ca	Other active systemic anti-cancer therapy	<6*
Metastatic Urothelial Ca	Avelumab (Bavencio)	<6*
Metastatic Urothelial Ca	Carboplatin single agent or in any other combination	<6*
Metastatic Urothelial Ca	Other active systemic anti-cancer therapy	<6*
Metastatic Urothelial Ca	Palliative	<6*
Urothelial	Atezolizumab (Tecentriq)	0
Urothelial	Carboplatin with Gemcitabine	0
Urothelial	Carboplatin with Paclitaxel	0
Urothelial	Cisplatin with Gemcitabine	0
Urothelial	Cisplatin with Gemcitabine + Nivolumab (Opdivo)	0
Urothelial	Enfortumab Vedotin + Pembrolizumab (Padcev + Keytruda)	N/A
Urothelial	Nivolumab (Opdivo)	0
Urothelial	Pembrolizumab (Keytruda)	0

The Data shows the number of unique patients treated with the above, as such some of these patients may have received more than one of these drugs/treatments.

* Where the figure provided is less than 6, and where simple calculations could identify fields that contain less than 6, the Trust has applied an exemption under Section 40(2) (personal data) of the Freedom of Information Act 2000. This is because the Trust believes there is a potential risk of individuals being able to be identified if the figures were disclosed.

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.
Velindre University NHS Trust is happy to receive communication in Welsh or English.



Question Two:

Does your trust participate in any ongoing clinical trials for the treatment of urothelial cancer? If so, can you please provide the name of each trial along with the number of patients taking part?

Duravelo-2 - A Randomized Open-Label Phase 2/3 Trial of BT8009 Monotherapy or in Combination in Participants with Locally Advanced or Metastatic Urothelial Cancer
Recruitment = 0 (study in setup)

IO102-IO103-022/ IOB – 022 - A Phase II Multi-Arm (basket) Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination with Pembrolizumab, as First-line Treatment for Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC), Squamous Cell Carcinoma of Head and Neck (SCCHN), or Metastatic Urothelial Bladder Cancer (mUBC)
Recruitment = 8

I trust this answers your request for information, however, should you not be satisfied with the information supplied or the process of supplying it, you have a right to complain and request a review. Please note that you must submit a request for a review within 40 days of the date of this letter.

You should forward your complaint to:

Mr Ian Bevan via FOI.VUNHST@wales.nhs.uk
Head of Information Governance
Velindre University NHS Trust
2, Charnwood Court
Heol Billingsley
Parc Nantgarw
Cardiff / Caerdydd
CF15 7QZ

Should you wish to take your complaint further, if you are still unhappy with the decision after review, you can contact the:

Information Commissioner's Office - Wales
2nd Floor Churchill House
Churchill Way
Cardiff
CF10 2HH
Telephone: 0330 414 6421
email: wales@ico.org.uk

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.
Velindre University NHS Trust is happy to receive communication in Welsh or English.



Pencadlys Ymddiriedolaeth GIG Prifysgol Felindre
Velindre University NHS Trust Headquarters
2 Cwrt Charnwood
Heol Billingsley
Parc Nantgarw
Caerdydd/Cardiff
CF15 7QZ
Ffôn/Phone : (029) 20196161
<https://velindre.nhs.wales>

Yours sincerely

**Non Gwilym
Interim Director of Corporate Governance**

Velindre University NHS Trust
2 Charnwood Court
Heol Billingsley
Parc Nantgarw
Cardiff
CF15 7QZ

Mae Ymddiriedolaeth GIG Prifysgol Felindre yn hapus i dderbyn gohebiaeth yn y Gymraeg neu'r Saesneg.
Velindre University NHS Trust is happy to receive communication in Welsh or English.

